Novel issues in the combined modality treatment of lymphomas
Novel venetoclax combination therapy advancing the field of CLL
Can ibrutinib be used as a first-line treatment in CLL?
Is the era of chemotherapy over in CLL?
John Gribben et al.
PEP-C for treatment of relapsed/refractory lymphoma